Member Info for Aberdeenman

A bit of further info on the rules/process.... When a company announces an RTO they have 6 months to complete the deal or delist, the shares suspending on announcement of the RTO. If the company fails to complete the deal within 6 months they have to delist, where we are now. they then have a further 6 months to complete where they can publish a prospectus and do a simple relist. If they fail to complete the deal within the second six months they have to apply to the market to relist same as if they were a new company, an expensive process that can cost in the region of 600k. therefore there is impetus to relist within the 12 month period, although they can apply for an extension of the 12 months if they are very close to closing the deal and/or there are extenuating circumstances (like bureaucratic delays) Obviously in each circumstance they have to get shareholder approval (EGM) for the proposed deal. therefore they publish the prospectus and announce the EGM giving two weeks notice. On approval the company normally relists the following business day.

If anyone wants more info on the process, have a look at the NFX RNS history, they did the same thing. Obviously different company, different deal, so don't read anything else into it apart from the process.

Thanks Red. As I said info will be able to be verified prior to relisting when the prospectus comes out, 2 weeks prior to the EGM. Just need that takeover panel approval first.

Just to add Red, as this is suspended, there is no advantage to be gained in anything I have said, but I could see that some peeps were getting very worried about what is happening, believe me I have been there, so much better to put out some info to try alleviate some concerns.

Hi Red, got it from 'a source' Sorry I cannot be more specific, but expecting deal to be done in two stages. First will be placing for �4-6m, on approval for deal to be done (EGM). There will be a much much larger sum raised. From what I hear the funding is already sorted for both stages, with the latter just under 200m no-one needs to believe me, but all will become clear in a couple of weeks or so, I can be judged then. first bit to get through is approval from the takeover panel, but doubt there will be any issue there. Also from what I here, there was much more money looking to invest than has been agreed (very oversubscribed), which bodes well for the relisted share price. Given also, once constructed, this will be a very profitable enterprise generating significant revenue, it would seem to be a very good investment. As for CTAG, what can you do with a CEO who lies? Been caught out with that on a few others lately, so am restricting my investments to where I am certain of what the company is doing and there is integrity in those running/behind the company, which is the case here. The very large investment is coming from a very small number of investors, and I expect a new high profile appointment also. finally also expecting a share consolidation, which is sensible on relisting.

Hi stay, think the 24th is a little optimistic, documents about to go to takeover panel, and expecting relist next month. Very large deal! prospectus will be out after takeover panel approval (should be very quick), then EGM called, two weeks after EGM announcement. If vote approved, then relists following (market) day. Been a long slog but given the size of the deal hoping there will be a decent uplift on listing. On the subject of share certificates, it is likely those who held in an ISA will have had share certificates issued, as the 'delisted' company shares cannot be held in an ISA, but some brokers are slower than others.

Another few weeks all will be fine, nothing to worry about here. EGM, shareholders approve deal, then trading again

Pharma trades on a P/E multiple of ~24 China market is much smaller than American and next drug is MUCH more lucrative than the one just licensed extrapolate based on the above and you realise this is well undervalued broker note revised significantly upwards next week

Put a £ sign before the number of shares you have, they expect to get taken out for between £400m and £1B within 2 years. ZERO requirement for dilution

Much more news coming, and watch out for a double digit revised broker note

No sign of the trolls today, they got this badly wrong and gave me so much abuse f**k them, I was right. Much more coming here, this is truly the start. ZERO requirement for dilution, you will hear more on that next week. No down side here I can see. Trolls tried to say risk from trials, I spoke with the CEO on that one, they know what the results will be, just a hoop they have to jump through.

Anyway, this will sort itself out if a day or two. Off away for a few days so will not be posting much No need to watch this if you are holding longer term like myself. Just wish the brokers had got this sorted earlier. Will listen to the interview later today.

REDUCED RISK Nuformix's approach uses existing drug molecules, with a history of safe use: No new safety data is required if staying within existing exposure limits, allowing rapid entry to both clinic and market Existing clinical data better informs decision making in future development Reduced time and cost of achieving clinical proof-of-concept and increasing success rates versus traditional biotech models NO NEW SAFETY DATA IS REQUIRED https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/

Prof Chris Frampton Chris is a co-founder and operates as the company�s Chief Scientific Advisor. A world-renowned X-Ray Crystallographer, Chris holds both academic and commercial roles and featured in Medicine Maker�s �Top 100 Most Influential Medicine Maker Power List� in April 2015. Chris was also a Cofounder, Director and Chief Scientific Officer of Pharmorphix Ltd (July 2003), acquired by SAFC Pharma in August 2006. Previously, Chris was Director of Strategic Marketing at Bruker AXS where he was responsible for new technology in the bio-market. More recently, Chris has taken up a Chair in Structural Chemistry and Crystal Engineering within the Wolfson Centre for Materials Processing at Brunel University and holds the post of Research Associate of Girton College, University of Cambridge. Chris is also founder and CEO of RBar3, a crystallographic consultancy. Great thing about this company is it is run by the best in their field. https://nuformix.com/about-nuformix/advisory-board/

rnorth, That is not the Podcast. The podcast is an Interview with Dr Dan Gooding, CEO. Will be out at lunchtime via Vox Markets

Usually about 12:30 it comes out. Spoke with my broker, he said lots of issues as it is a Shell relisting with a name change, but should be sorted in a day or so. Also look out for articles in National news ;-)

All major shareholders have voluntarily locked themselves in for 9 - 15 months, shows the level of confidence here.

http://www.studiohansa.com/work/nuformix/ Explains more about this

Nonsense. already clear there will be an early commercial deal

Fibrosis is a degenerative disease affecting most vital organs. Healthy tissue becomes scarred and impaired, ultimately resulting in organ failure. Fibrotic conditions (e.g. lung fibrosis) are typified by high patient mortality and are globally recognized as a major unmet medical need. Despite alarming growth rates, current treatments are either non-existent or offer marginal clinical benefits whilst causing side effects so severe that many patients elect to stop treatment. Why NXP002? NXP002 targets a key mechanistic pathway shared by many forms of fibrosis, meaning effective oral delivery of NXP002 could treat multiple fibrotic diseases. Despite demonstrable promise in several fibrotic conditions, poor oral efficacy of the currently marketed drug form means it is unable to exploit it�s full anti-fibrotic potential. Nuformix�s ongoing robust pre-clinical programme, running in parallel to Human PK studies, has demonstrated how NXP002 can safely inhibit multiple forms of fibrosis in greater depth. NXP002�s cocrystal drug form will enable consistent and efficacious oral delivery, creating the potential to treat multiple fibrotic conditions whilst removing severe treatment side effects. NXP002 is an example of Nuformix�s strategy to use an approved drug with a strong safety profile in new indications. Recognised safety and human precedence combine to reduce development risk and increase speed to clinic versus traditional biotech models. Note last two paragraphs for those unfamiliar with how this works regarding testing..... https://nuformix.com/pipeline/nxp002-fibrosis/ Going to be MASSIVE IMO